US 12,329,732 B2
Citrulline for treatment of sickle cell crisis
Marshall L. Summar, Washington, DC (US); Frederick E. Barr, Little Rock, AR (US); and Suvankar Majumdar, Rockville, MD (US)
Assigned to Vanderbilt University, Nashville, TN (US); and The University of Mississippi Medical Center, Jackson, MS (US)
Filed by Vanderbilt University, Nashville, TN (US)
Filed on Jun. 3, 2022, as Appl. No. 17/832,058.
Application 17/832,058 is a continuation of application No. 15/906,852, filed on Feb. 27, 2018, granted, now 11,351,135.
Claims priority of provisional application 62/463,931, filed on Feb. 27, 2017.
Prior Publication US 2022/0304966 A1, Sep. 29, 2022
Int. Cl. A61K 31/198 (2006.01); A61K 9/00 (2006.01); A61P 7/06 (2006.01)
CPC A61K 31/198 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0073 (2013.01); A61P 7/06 (2018.01)] 19 Claims
 
1. A method of treating a complication resulting from one or more occlusions formed during sickle cell crisis, the method comprising intravenously administering a bolus of a composition to a patient suffering from sickle cell crisis, wherein the composition comprises an effective amount of citrulline to manage sickle cell crisis, wherein the sickle cell crisis comprises vaso-occlusive crisis, acute chest syndrome, sequestration crisis, or a combination thereof, and wherein the complication resulting from the one or more occlusions comprises restriction of blood flow to an organ.